Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.73 |
| ▸ | ESRRA | P11474 | 8/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586208 | 0.85 | ESR2 (1.00) | ESR1ESR2ESRRA | |
| SCHEMBL2589073 | 0.82 | ESR1 (0.76) | ESR1ESR2ESRRANPC1RAB9A | |
| SCHEMBL2589588 | 0.82 | ESRRA (1.00) | ESR1ESR2ESRRA | |
| SCHEMBL14924057 | 0.78 | ESR2 (0.76) | ESR1ESR2ESRRANPC1RAB9A | |
| SCHEMBL14138429 | 0.71 | ESR2 (0.75) | ESR1ESR2ESRRA | |
| SCHEMBL2592602 | 0.71 | ESR2 (0.74) | ESR1ESR2ESRRAALDH1A1 | |
| SCHEMBL14924032 | 0.71 | ESR2 (0.74) | ESR1ESR2ESRRA | |
| SCHEMBL2592071 | 0.69 | ESR2 (1.00) | ESR1ESR2ESRRA | |
| SCHEMBL13097499 | 0.69 | ESR2 (0.71) | ESR1ESR2ESRRA | |
| SCHEMBL13969816 | 0.69 | ESR2 (0.71) | ESR1ESR2ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | claimed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | claimed |
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039820-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | GTX, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | ESR1 168/4885ESR2 511/4885ESRRA 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.